Novartis AG Stock News

Attempting to time the market is not a successful strategy. Long-term investing has consistently outperformed market timing. Today, the S&P is fairly valued, but blue-chip bargains are plentiful if yo

The pharmaceutical sector mainstay posted its first-quarter results. It beat on both the top and bottom lines.

Novartis AG (ADR) (NYSE:NVS) has raised its full-year revenue and profit guidance following a strong first quarter driven by momentum in key products including psoriasis drug Cosentyx, relapsing Multi

Vas Narasimhan, Novartis CEO, joins 'Money Movers' to discuss what feeds the company's strong guidance, if pricing in the U.S. will involve some friction, and more.

American depositary receipts (ADRs) of Novartis (NVS) rose in intraday trading Tuesday as the Swiss-based pharmaceutical firm reported better-than-expected first-quarter results and boosted its guidan

The headline numbers for Novartis (NVS) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimate

Novartis (NVS) comfortably beats first-quarter earnings and sales estimates. The company ups its outlook for 2024 on strong growth across key brands.

Novartis CEO Vas Narasimhan said the company saw a very good performance across both established medicines and recent drug launches. "While there was a small contribution from generics getting pushed

Novartis shares rallied on Tuesday as the Swiss drugmaker raised its outlook for the year after seeing strong demand for heart and psoriasis drugs.

Shares of Swiss drugmaker Novartis climbed 4.8% in early deals Tuesday after it raised its full-year guidance following better-than-expected first-quarter results.

Novartis lifted its full-year guidance after first-quarter profit and sales rose and beat consensus expectations, boosted by strong sales of key drugs.

Swiss drugmaker Novartis on Tuesday raised its full-year guidance after reporting better-than-expected first-quarter results.

Novartis (NVS) key drugs Entresto, Kisqali and Pluvicto are likely to have fueled its top and bottom-line numbers in the first quarter.

Evaluate the expected performance of Novartis (NVS) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics fo

Bristol Myers Squibb is turning on its innovative machine to get through recent patent cliffs. Novartis recently became a thinner company that is laser-focused on developing new medicines.